Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.

"LM, GG, EDM, NM, MP, LP, SP, MCC, and ADB declare no conflict of interest. AP has declared consulting fees/advisory role for Amgen, MSD, Novartis, travel and accommodation by Pfizer. AF has declared consulting fees/advisory role for AstraZeneca, Daiichi Sankyo, Eisai, Eli-Lilly. Epionpharma, exact science, MSD, Novartis, Pierre Fabre, Roche, Seagen. GT is supported by funds of Ministero della Salute (Ricerca Corrente 2022). EB is currently supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) under Investigator Grant (IG) No. IG20583. EB is supported by institutional funds of Università Cattolica del Sacro Cuore (UCSC-project D1). EB is supported by funds of Ministero della Salute (Ricerca Corrente 2022). EB received speakers’ and travels’ fee from MSD, AstraZeneca, Pfizer, Eli-Lilly, BMS, Novartis, and Roche. EB received institutional research grants from AstraZeneca, Roche. AO has declared consulting fees/advisory role for Novartis, Roche, Eli-Lilly, Amgen, Daiichi Sankyo and travel and accommodation by Daiichi Sankyo, Novartis, Roche, and Pfizer."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

"This systematic review and meta-analysis has been performed in accordance with the Methodological Expectations of Cochrane Intervention Reviews standards and reported following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement (Supplemental Table S1). The protocol was registered to PROSPERO (CRD42022332787). Registration:: PROSPERO identifier: CRD42022332787."